UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2008

AVANT Immunotherapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware

Commission file number 0-15006

13-3191702

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

	119 Fourth Avenue Needham, Massachusetts 02494
	(Address of principal executive offices, including zip code)

(781) 433-0771
(Registrant’s telephone number, including area code)

(Former name, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On August 6, 2008, AVANT Immunotherapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2008. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AVANT Immunotherapeutics, Inc.


Dated:	August 6, 2008	By:	/s/ Avery W. Catlin
			Avery W. Catlin
			Senior Vice President and
			Chief Financial Officer


99.1	Press Release of AVANT Immunotherapeutics, Inc., dated August 6, 2008.